Although tyrosine kinase inhibitors (TKIs) have largely replaced hematopoietic cell transplantation (HCT) as first-line treatment for chronic myeloid leukemia (CML), the authors of this review note that HCT remains a curative option for accelerated/blastic-phase CML and selected chronic-phase CML. Strategies for optimizing HCT outcomes include pre- and post-transplant TKI administration, choice of conditioning regimen, GVHD prophylaxis, BCR-ABL monitoring, and relapse management. The authors discuss current controversies in HCT, including transplant timing, pediatric CML, fertility preservation, alternative donors, and economics.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: Role of HCT for CML in the 21st Century
Apr 2015